This is an open-label continuation study designed to monitor the safety, tolerability and effectiveness of lurasidone in subjects who have completed participation in a lurasidone extension study (NCT00868959 and NCT01566162) and who may benefit from continued treatment with lurasidone.

Inclusion Criteria:

• The subject or legal guardian provides written informed consent. For eligible subjects under age 18, verbal assent is also required.
• The subject has completed the extension phase of a prior lurasidone clinical study. Eligible subjects may enroll into this continuation study directly (or within 10 days) after completing the extension phase of a prior lurasidone clinical study. Subjects that have completed an extension study prior to the initiation of this protocol at the study site, may participate in this study up to 3 months after completion of the extension phase of the prior lurasidone study.
• The subject is judged by the Investigator to be suitable for participation in a clinical study involving open-label lurasidone treatment and is able to comply with the protocol.
• The subject, in the Investigator's judgment, may benefit from continued treatment with lurasidone

Exclusion Criteria:

• The subject is considered by the Investigator, to be at imminent risk for homicidal or suicidal behavior.
• The subject resides in a country where lurasidone has been approved for any indication.
• The subject is currently enrolled in any other investigational study.
• The subject answers "yes" to "Suicidal Ideation" Items 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS).